Peptide-based vaccines for cancer therapy

Giorgio Parmiani, Vincenzo Russo, Cristina Maccalli, Danilo Parolini, Nathalie Rizzo, Michele Maio

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Interest for cancer vaccination started more than 30 years ago after the demonstration that both in animal models and later on in patients it is possible to generate anti-tumor immune responses. The clinical application of this knowledge, however, was disappointing. In this review we summarize results on peptides epitopes recognized by T cells that have been studied thanks to their easy synthesis and the lack of significant side effects when administered in-vivo. To improve the clinical efficacy, peptides were modified in their aminoacid sequence to augment their immunogenicity. Peptides vaccines were recently shown to induce a high frequency of immune response in patients that were accompanied by clinical efficacy. These data are discussed at the light of recent progression of immunotherapy caused by the addition of check-point antibodies thus providing a general picture of the potential therapeutic efficacy of the peptide-based vaccines and their combination with other biological agents.

Original languageEnglish
Pages (from-to)3175-3178
Number of pages4
JournalHuman Vaccines and Immunotherapeutics
Volume10
Issue number11
DOIs
Publication statusPublished - 1 Nov 2014
Externally publishedYes

Fingerprint

Active Immunotherapy
Subunit Vaccines
Peptides
T-Lymphocyte Epitopes
Biological Factors
Immunotherapy
Neoplasms
Vaccination
Animal Models
Light
Antibodies
Therapeutics

Keywords

  • Antigens
  • Cancer
  • Epitopes
  • Immune responses
  • Vaccination

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Parmiani, G., Russo, V., Maccalli, C., Parolini, D., Rizzo, N., & Maio, M. (2014). Peptide-based vaccines for cancer therapy. Human Vaccines and Immunotherapeutics, 10(11), 3175-3178. https://doi.org/10.4161/hv.29418

Peptide-based vaccines for cancer therapy. / Parmiani, Giorgio; Russo, Vincenzo; Maccalli, Cristina; Parolini, Danilo; Rizzo, Nathalie; Maio, Michele.

In: Human Vaccines and Immunotherapeutics, Vol. 10, No. 11, 01.11.2014, p. 3175-3178.

Research output: Contribution to journalArticle

Parmiani, G, Russo, V, Maccalli, C, Parolini, D, Rizzo, N & Maio, M 2014, 'Peptide-based vaccines for cancer therapy', Human Vaccines and Immunotherapeutics, vol. 10, no. 11, pp. 3175-3178. https://doi.org/10.4161/hv.29418
Parmiani G, Russo V, Maccalli C, Parolini D, Rizzo N, Maio M. Peptide-based vaccines for cancer therapy. Human Vaccines and Immunotherapeutics. 2014 Nov 1;10(11):3175-3178. https://doi.org/10.4161/hv.29418
Parmiani, Giorgio ; Russo, Vincenzo ; Maccalli, Cristina ; Parolini, Danilo ; Rizzo, Nathalie ; Maio, Michele. / Peptide-based vaccines for cancer therapy. In: Human Vaccines and Immunotherapeutics. 2014 ; Vol. 10, No. 11. pp. 3175-3178.
@article{4fb57c46c6b04cd48f65062f3dfed1f5,
title = "Peptide-based vaccines for cancer therapy",
abstract = "Interest for cancer vaccination started more than 30 years ago after the demonstration that both in animal models and later on in patients it is possible to generate anti-tumor immune responses. The clinical application of this knowledge, however, was disappointing. In this review we summarize results on peptides epitopes recognized by T cells that have been studied thanks to their easy synthesis and the lack of significant side effects when administered in-vivo. To improve the clinical efficacy, peptides were modified in their aminoacid sequence to augment their immunogenicity. Peptides vaccines were recently shown to induce a high frequency of immune response in patients that were accompanied by clinical efficacy. These data are discussed at the light of recent progression of immunotherapy caused by the addition of check-point antibodies thus providing a general picture of the potential therapeutic efficacy of the peptide-based vaccines and their combination with other biological agents.",
keywords = "Antigens, Cancer, Epitopes, Immune responses, Vaccination",
author = "Giorgio Parmiani and Vincenzo Russo and Cristina Maccalli and Danilo Parolini and Nathalie Rizzo and Michele Maio",
year = "2014",
month = "11",
day = "1",
doi = "10.4161/hv.29418",
language = "English",
volume = "10",
pages = "3175--3178",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "11",

}

TY - JOUR

T1 - Peptide-based vaccines for cancer therapy

AU - Parmiani, Giorgio

AU - Russo, Vincenzo

AU - Maccalli, Cristina

AU - Parolini, Danilo

AU - Rizzo, Nathalie

AU - Maio, Michele

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Interest for cancer vaccination started more than 30 years ago after the demonstration that both in animal models and later on in patients it is possible to generate anti-tumor immune responses. The clinical application of this knowledge, however, was disappointing. In this review we summarize results on peptides epitopes recognized by T cells that have been studied thanks to their easy synthesis and the lack of significant side effects when administered in-vivo. To improve the clinical efficacy, peptides were modified in their aminoacid sequence to augment their immunogenicity. Peptides vaccines were recently shown to induce a high frequency of immune response in patients that were accompanied by clinical efficacy. These data are discussed at the light of recent progression of immunotherapy caused by the addition of check-point antibodies thus providing a general picture of the potential therapeutic efficacy of the peptide-based vaccines and their combination with other biological agents.

AB - Interest for cancer vaccination started more than 30 years ago after the demonstration that both in animal models and later on in patients it is possible to generate anti-tumor immune responses. The clinical application of this knowledge, however, was disappointing. In this review we summarize results on peptides epitopes recognized by T cells that have been studied thanks to their easy synthesis and the lack of significant side effects when administered in-vivo. To improve the clinical efficacy, peptides were modified in their aminoacid sequence to augment their immunogenicity. Peptides vaccines were recently shown to induce a high frequency of immune response in patients that were accompanied by clinical efficacy. These data are discussed at the light of recent progression of immunotherapy caused by the addition of check-point antibodies thus providing a general picture of the potential therapeutic efficacy of the peptide-based vaccines and their combination with other biological agents.

KW - Antigens

KW - Cancer

KW - Epitopes

KW - Immune responses

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=84921761156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921761156&partnerID=8YFLogxK

U2 - 10.4161/hv.29418

DO - 10.4161/hv.29418

M3 - Article

C2 - 25483658

AN - SCOPUS:84921761156

VL - 10

SP - 3175

EP - 3178

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 11

ER -